Abstract:Introduction The gastrointestinal tract is the most common extranodal site involved in non-Hodgkin lymphoma (NHL) and most NHL cases are of B-cell origin. Peripheral T-cell lymphoma (PTCLs) involving the gastrointestinal is less commont, comprising only about 4-6% of gastrointestinal lymphomas. This study retrospectively analyzed the clinical characteristics and potential clinical factors influencing survival outcomes in patients diagnosed with PTCLs through gastrointestinal tissue biopsy at our center. Methods Based on the clinical data, patients were reevaluated for clinical staging and risk stratification, including Ann Arbor staging, IPI scoring, and gastrointestinal lymphoma Lugano staging. Patient's follow-up was conducted through outpatient medical records and telephone communication. For the analysis of categorical data, the chi-square test or Fisher's exact test was used. Survival time was estimated using the Kaplan-Meier method. The Cox proportional hazards model was employed to calculate hazard ratios (HR) and their 95% confidence intervals (CI) to analyze prognostic factors. Data analysis was performed using SPSS 23 for Windows software. Results A total of 622 gastrointestinal tissue biopsy samples from October 2014 to September 2022 were retrieved from the medical records system. Among them, 67 cases (10.8%) were diagnosed as PTCLs. Among them, 5 cases had no available clinical data and were excluded. Detailed information regarding patient clinical characteristics can be found in the table. Treatment and Efficacy: Among the 62 patients with available clinical data, 43 received gastrointestinal surgical resection treatment, including 21 cases (33.9%) of elective non-emergency surgery and 22 cases (35.5%) of emergency surgery due to acute abdomen. The median courses of chemotheray was 5 (1~8). 15 patients (31.3%) achieved complete response (CR)/CRu; 10 patients (20.8%) achieved partial response (PR). Among the 59 patients who received chemotherapy and/or surgical treatment, progression-free survival (PFS) was evaluated with a median follow-up time of 48.4 months, and the median PFS was 4.4 months (95% CI: 2.5-6.3) (Figure). Multivariate analysis identified advanced Ann Arbor stage (stage 3/4) (HR=3.53, 95% CI: 1.53-8.17, P=0.003) as independent adverse prognostic factors for PFS. Receiving chemotherapy (HR=0.24, 95% CI: 0.09-0.66, P=0.005) and elective surgery (HR=0.45, 95% CI: 0.22-0.92, P=0.029) were identified as independent favorable prognostic factors for PFS. As of the last follow-up, a total of 49 patients (79.0%) had died and the median overall survival (OS) was 6.4 months (95% CI: 3.8-8.9) (Figure). Multivariate analysis identified Ann Arbor stages 3-4 (HR=3.01, 95% CI: 1.34-6.74, P=0.007) as an independent adverse prognostic factor for OS, and receiving chemotherapy (HR=0.13, 95% CI: 0.05-0.31, P<0.001), elective surgery (HR=0.36, 95% CI: 0.16-0.74, P=0.006) were identified as independent favorable prognostic factors for OS. Conclusion Data from four hematological disease treatment centers located in Zhejiang Province, southeastern China, showed that PTCLs involving the gastrointestinal tract accounted for approximately 10.8% (67/622) of all gastrointestinal lymphoma patients. These patients had a relatively high incidence of gastrointestinal perforation (35.5%). The overall treatment efficacy for patients was poor, with a majority of them succumbing to disease progression. The median PFS and OS were approximately six months. Elective surgery and chemotherapy appeared to improve the patients' outcomes.

Clinicopathological characteristics and prognostic factors of primary gastrointestinal lymphoma: a 22-year experience from South China.

Clinical Characteristics Analysis of Gastrointestinal Peripheral T-Cell Lymphoma:Impact of Non-Emergency Surgery on Overall Survival

[Clinical Study of 22 Cases of Primary Gastrointestinal Lymphoma].

Clinicopathologic Features and Treatment Outcome of Primary Intestinal Non-Hodgkin Lymphoma: A Single Center Experience.

Clinical analysis of 33 cases of primary gastrointestinal malignant lymphoma

[Long Term Follow-Up and Prognostic Analysis of 85 Cases with Primary Gastrointestinal Diffuse Large B Cell Lymphoma].

[Clinical and Prognostic Analysis of 101 Cases of Primary Gastrointestinal Non-Hodgkin's Lymphoma].

Clinicopathological analysis of 34 cases of primary small intestine lymphoma

[Clinical Characteristics, Cell Origin and Prognosis of Primary Gastrointestinal Diffuse Large B-cell Lymphoma: a Report of 40 Cases].

[Analysis of Clinical Characteristics and Prognostic Factors of 110 Cases with Primary Gastrointestinal Tract Non-Hodgkin's Lymphoma].

Clinical analysis of 69 patients with primary gastric diffuse large B-cell lymphoma

Clinical, Endoscopic, Pathologic and Prognostic Factors of Primary Gastric Lymphoma

Clinical and endoscopic features of primary small bowel lymphoma: a single-center experience from mainland China

High IL-10 Expression is Associated with Poor Prognosis in Primary Gastrointestinal Lymphoma

Diagnosis and Treatment of Primary Gastrointestinal Malignant Lymphoma (a Report of 35 Cases)

Clinical analysis of 41 cases primary gastric lymphoma

[Clinicopathological characteristics and prognostic analysis of 92 cases with primary gastrointestinal diffuse large B-cell lymphoma].

CLINICAL FEATURES AND PROGNOSES OF PRIMARY GASTRIC DIFFUSE LARGE B CELL LYMPHOMA: A RETROSPECTIVE ANALYSIS OF 139 CHINESE CASES WITH IMMUNOPHENOTYPING FROM CLAP

[Clinical features, diagnosis, treatment, and prognosis of 99 cases with primary intestinal lymphoma].

Prognostic Analysis of Primary Gastrointestinal Diffuse Large B-cell Lymphoma

Primary intestinal diffuse large B-cell lymphoma: novel insights and clinical perception